NICE (TASE:NICE) Wins Bluecrest Deal After AI Narrative Puts Valuation Back In Focus
News around NICE (TASE:NICE) today centers on Bluecrest Health Intelligence’s move to an AI-enabled contact center model using the CXone platform, highlighting how the company’s technology is being applied in real-world healthcare operations.
Despite the Bluecrest win and other recent CXone client additions, momentum in NICE’s share price has been mixed. The company has a 90-day share price return of 12.09%, a year-to-date share price decline of 14.53%, and a 1-year total shareholder return that is down 32.57%.
Scan other AI driven customer engagement stocks showing strong execution traits by reviewing our curated group of 73 profitable AI stocks that aren't just burning cash along with NICE's latest CXone momentum.
NICE now sits between fresh AI contract momentum and a share price that has fallen sharply over the past year. Does it make more sense to step in after this rebound or hold out for a cheaper entry?
Most Popular Narrative: 50% Undervalued
The most followed narrative on NICE values the shares at ₪620.96, roughly double the last close of ₪310.5, and anchors that view in AI driven cloud adoption.
The rapid growth in demand for AI-driven customer experience solutions, manifested by 42% year-over-year growth in AI and self-service ARR and the upcoming integration of Cognigy's conversational AI capabilities, provides visibility into sustained increases in high-margin, recurring cloud revenue and expanded ARPU.
Want to see what bridges that gap between NICE's current price and this higher fair value? The narrative leans heavily on recurring cloud revenue, margin assumptions, and a different earnings mix over time.
Result: Fair Value of ₪620.96 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, NICE investors still need to watch for pressure on margins from heavier cloud and international spending, as well as higher churn in acquired customers such as LiveVox.
Find out about the key risks to this NICE narrative.
Next Steps
With mixed signals around NICE, it helps to see both the caution and the optimism in one place, then test the data yourself and move quickly to shape your own view with 2 key rewards and 1 important warning sign
Looking for more investment ideas beyond NICE?
If NICE has your attention, do not stop there. Use the Simply Wall Street Screener to compare other stocks and sharpen your next move.
- Target potential mispricing by running through our collection of 265 high quality undervalued stocks that pair quality fundamentals with more modest market expectations.
- Prioritise resilience first and scan a curated set of 313 resilient stocks with low risk scores that emphasise financial strength and fewer red flags.
- Hunt for under-the-radar opportunities by checking a focused group of 615 high quality undiscovered gems before they attract wider attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com